MedTrace Logo

BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants

NCT04669262 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-10-26

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to investigate the safety and tolerability of BGB-DXP604 alone and in combination with BGB-DXP593 in healthy participants

Conditions

  • Healthy

Interventions

DRUG

BGB-DXP604

Administered as intravenous (IV) infusion over 30 to 60 minutes

DRUG

BGB-DXP593

Administered as intravenous (IV) infusion over 30 to 60 minutes

DRUG

Placebo

Placebo to match BGB-DXP593

DRUG

Placebo

Placebo to match BGB-DXP604

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Principal Investigators

  • Study Director · BeiGene

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-09
Primary Completion
2021-05-21
Completion
2021-05-21

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04669262 on ClinicalTrials.gov